US Stock MarketDetailed Quotes
CYTO Altamira Therapeutics
- 0.6021
- +0.0120+2.03%
Close Oct 16 16:00 ET
- 0.5902
- -0.0119-1.98%
Post 17:53 ET
2.28MMarket Cap0.04P/E (TTM)
0.6200High0.5930Low79.66KVolume0.6060Open0.5901Pre Close48.45KTurnover2.12%Turnover RatioLossP/E (Static)3.78MShares17.200052wk High0.36P/B2.26MFloat Cap0.580052wk Low--Dividend TTM3.76MShs Float636800.0000Historical High--Div YieldTTM4.58%Amplitude0.5800Historical Low0.6080Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Altamira Therapeutics Stock Forum
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) --
Certification to ISO 13485 extended to also include production process
Supports Bentrio growth strategy together with strategic contract manufacturer and expanding network of international distributors
Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO) today announced tha...
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
Altamira Therapeutics (Nasdaq: CYTO) announced the expansion of its Bentrio® nasal spray license and distribution agreement with Nuance Pharma. The extended agreement now includes seven additional countries in East and South East Asia, covering a population of over 630 million. Nuance has successfully launched Bentrio in Hong ...
$Cingulate (CING.US)$ $SciSparc (SPRC.US)$ $VS MEDIA Holdings (VSME.US)$ $Altamira Therapeutics (CYTO.US)$ $Airship AI (AISP.US)$
📊⚡️📊
Abdominal aortic aneurysm (AAA) is a serious medical condition characterized by the localized abnormal enlargement of the abdominal aorta, the major blood vessel supplying blood to the lower part of the body. When an AAA ruptures, it poses a life-threatening situation, with more ...
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
Altamira Therapeutics (Nasdaq:CYTO) has announced the publication of a preclinical study demonstrating effective treatment of abdominal aortic aneurysm (AAA) using their SemaPhore™ nanoparticles to deliver SOD2 mRNA. The study, conducted by researchers from Washington University and the U...
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
Altamira Therapeutics, under the stock ticker CYTO, has highlighted a newly published review supporting the use of betahistine for managing residual dizziness in benign paroxysmal positional vertigo (BPPV) patients. The review, appearing in Frontiers in Neurology, suggests that betahistine, which is commonly used outside the US, can significantl...
No comment yet